MedRx Co., Ltd
Tokyo Stock Exchange 4586.T
MedRx Co., Ltd EBITDA Margin for the year ending December 31, 2023: -3,050.06%
-
MedRx Co., Ltd EBITDA Margin for the year ending December 31, 2022 was -1,773.65%, a 85.14% change year over year.
-
MedRx Co., Ltd EBITDA Margin for the year ending December 31, 2021 was -11,936.08%, a -1,207.89% change year over year.
-
MedRx Co., Ltd EBITDA Margin for the year ending December 31, 2020 was -912.62%, a 2.38% change year over year.
-
MedRx Co., Ltd EBITDA Margin for the year ending December 31, 2019 was -934.89%.
| Date | EBITDA Margin | EBIT Margin | Depreciation and Amortization | EBIT |
|---|
Don’t Miss A Beat
| CEO | Mr. Yonehiro Matsumura |
| IPO Date | Feb. 14, 2013 |
| Location | Japan |
| Headquarters | 431-7 Nishiyama |
| Employees | 22 |
| Sector | Health Care |
| Industries | |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email